Abstract 5053
Background
Colorectal mucinous carcinoma (MAC) is a distinct subtype of colorectal carcinoma (CRC) accounting for approximately 10-20% of all CRCs. Mucinous carcinomas characterized by the presence of abundant extracellular mucin which occupies at least 50% of the tumour volume. Patients are often diagnosed at an advanced stage in young patients showing a poor prognosis with the 3-year overall survival rate of 57%. Although clinicopathologic findings of colorectal MACs are relatively well known, their molecular alterations have not elucidated. We investigate molecular alterations of colorectal MACs revealed by next-generation sequencing (NGS).
Methods
We retrospectively reviewed cases of CRCs with mucinous component and 111 MACs subject to molecular profiling using NGS on the Ion Proton (Thermo Fisher Scientific). We examined substitutions and small indels in 409 cancer-related genes using Ion ampliseq Cancer Hotspot and Ion ampliseq Comprehensive Cancer panels.
Results
Of the 111 patients included in the analysis, 60 (54.1%) were male: the median age was 58 years. BRAF was mutated in 17% of colorectal MACs (19 of 111) and 9.0% of CRCs (18 of 200), V600E mutations were predominantly identified in MACs, representing 95% (18 of 19) of BRAF mutated cases (p = 0.0438). GNAS mutations were frequently detected in 14.4% of colorectal MACs (19 of 111) and 1.5% of CRC (3 of 200), R201C and R201H were more commonly mutated, representing 95% (18 of 19) of GNAS mutated cases (p < 0.001). SMAD4 mutations were frequently noted in colorectal MACs compared with those of CRCs (24 of 111 vs. 22 of 200, p = 0.0187).
Conclusions
This study demonstrates distinct genomic differences in colorectal MACs compare with CRCs. The genomic profiling of colorectal MACs revealed by NGS can identify potentially targetable molecular alterations in the majority of colorectal MACs (95.5%). Overall, colorectal MACs harbor relatively high frequencies of BRAF, GNAS, and SMAD4 mutations compared with those of CRCs. This distinct activating or inactivating mutations of these genes suggest promising consideration of targeted therapy by inhibiting related pathways in patients with advanced colorectal MACs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Mi Lee.
Funding
Jeju National University Hospital.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2674 - Multicenter Phase I Trial of Trastuzumab Emtansine (T-DM1) in Combination with Non-Pegylated Liposomal Doxorubicin (NPLD) in HER2[+] Metastatic Breast Cancer (MBC). THELMA Study
Presenter: Elena López-Miranda
Session: Poster Display session 2
Resources:
Abstract
1398 - Phase 1 study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumors: primary results of dose-escalation part
Presenter: Noboru Yamamoto
Session: Poster Display session 2
Resources:
Abstract
5818 - Polo-like Kinase 1 inhibitor onvansertib synergizes with paclitaxel in breast cancer carrying p53 mutation
Presenter: Antonio Giordano
Session: Poster Display session 2
Resources:
Abstract
5927 - Phase 1b study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173).
Presenter: Robert Wesolowski
Session: Poster Display session 2
Resources:
Abstract
1695 - Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: results from the AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: Poster Display session 2
Resources:
Abstract
1742 - Clinical profile and outcome of HER2 positive breast cancer patients with brain metastases treated with HER2 targeted therapy: Real world experience.
Presenter: Prabhat Bhargava
Session: Poster Display session 2
Resources:
Abstract
1846 - Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: results of single arm phase IV COMACHI study
Presenter: Norikazu Masuda
Session: Poster Display session 2
Resources:
Abstract
5385 - Anti HER-2 Therapies and Left Ventricular Dysfunction The Renaissance Study
Presenter: ANDRES DANIELE
Session: Poster Display session 2
Resources:
Abstract
3320 - Safety and efficacy of T-DM1 in 128 patients with advanced HER2+ breast cancer: The Royal Marsden experience.
Presenter: Nicolò Battisti
Session: Poster Display session 2
Resources:
Abstract
4540 - Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): challenges in assessing effectiveness of treatment sequencing in the real world (RW)
Presenter: Thibaut Sanglier
Session: Poster Display session 2
Resources:
Abstract